What is the recommended dosing, contraindications, and alternative treatments for etripamil (Cardamyst) in adults presenting with acute symptomatic paroxysmal supraventricular tachycardia?

Etripamil (Cardamyst) for Acute Paroxysmal Supraventricular Tachycardia

Etripamil is a novel intranasal calcium channel blocker that offers patients the ability to self-administer treatment for acute PSVT episodes outside healthcare settings, representing a paradigm shift from traditional IV-only therapies. However, it is important to note that the evidence provided does not contain FDA-approved labeling for etripamil specifically—the drug label references are for diltiazem (Cardamyst IV), not etripamil nasal spray.

Recommended Dosing

For acute PSVT episodes, administer etripamil 70 mg intranasally as a single dose, with an optional repeat 70 mg dose if symptoms persist beyond 10 minutes after the first dose. 1, 2

Administration Protocol:

• Apply ECG monitoring at symptom onset 2, 3
• Perform vagal maneuver first (Valsalva or carotid massage) 2, 3
• If vagal maneuver unsuccessful, administer first 70 mg dose intranasally 1, 2
• If symptoms persist at 10 minutes, administer second 70 mg dose 1, 2
• Continue ECG monitoring for at least 60 minutes post-administration 2, 3

Efficacy Timeline:

• Median time to conversion: 17.2 minutes (95% CI: 13.4-26.5) with the repeat-dose regimen 1
• Conversion rates by 30 minutes: 64% with etripamil versus 31% with placebo (HR 2.62; 95% CI 1.66-4.15; p<0.0001) 1
• Peak effect occurs within 4-7 minutes, with PR interval prolongation sustained for approximately 45 minutes 4

Contraindications and Precautions

While specific contraindications for etripamil are not detailed in the provided evidence, extrapolating from calcium channel blocker class effects and the diltiazem label, avoid etripamil in:

• Hemodynamically unstable patients (use synchronized cardioversion instead) 5
• Patients with systolic heart failure or impaired ventricular function 5
• Wide-complex tachycardias or pre-excited atrial fibrillation 5
• Severe hypotension or cardiogenic shock 6
• Second- or third-degree AV block (unless pacemaker present) 6

Important Drug Interactions (based on calcium channel blocker class):

• Avoid concurrent use with rifampin (CYP3A4 inducer that reduces diltiazem levels to undetectable) 6
• Reduce dose if patient taking dipyridamole or carbamazepine 5
• Use caution with beta-blockers (avoid serial administration due to overlapping effects and risk of profound bradycardia) 5

Safety Profile

Etripamil demonstrates an excellent safety profile with predominantly mild-to-moderate, transient adverse events localized to the nasal administration site. 1, 2

Common Adverse Events:

• Nasal discomfort: 30.2% of patients 2
• Nasal congestion: 13.9% 2
• Rhinorrhea: 13.1% 2
• Epistaxis: 7.4% 2

Critical Safety Findings:

• No serious adverse events related to etripamil reported 1
• No episodes of symptomatic hypotension, bradyarrhythmias, AV block, or sinus pauses ≥3 seconds 4, 7
• Adverse event frequencies decrease with repeated use across multiple PSVT episodes 2
• All adverse events resolved without intervention 1

Alternative Treatments

When etripamil is unavailable or contraindicated, follow the established treatment algorithm based on hemodynamic stability:

For Hemodynamically Stable Patients:

1. First-line: Vagal maneuvers (Valsalva for 10-30 seconds or carotid massage for 5-10 seconds in supine position) 5

2. Second-line: Adenosine 6 mg IV rapid push, followed by 12 mg if needed (terminates AVNRT in ~95% of patients) 5

   • Reduce initial dose to 3 mg in patients taking dipyridamole, carbamazepine, or with transplanted hearts 5
   • Contraindicated in asthma 5

3. Third-line: IV calcium channel blockers or beta-blockers 5

   • Diltiazem: 15-20 mg (0.25 mg/kg) IV over 2 minutes; repeat 20-25 mg (0.35 mg/kg) at 15 minutes if needed 5, 6
   • Verapamil: 2.5-5 mg IV over 2 minutes (3 minutes in elderly); repeat 5-10 mg every 15-30 minutes to maximum 20 mg 5
   • IV beta-blockers (esmolol, metoprolol) are reasonable but less effective than diltiazem 5

4. Fourth-line: Synchronized cardioversion if pharmacological therapy fails or is contraindicated 5

For Hemodynamically Unstable Patients:

Proceed immediately to synchronized cardioversion if adenosine and vagal maneuvers fail or are not feasible 5

Ongoing Management:

• Oral verapamil or diltiazem for patients not candidates for catheter ablation 5
• Catheter ablation of slow pathway is first-line definitive therapy with >95% success rate and <1% risk of AV block 5

Clinical Advantages of Etripamil

Etripamil addresses a critical unmet need by enabling patient self-treatment outside healthcare settings, potentially reducing emergency department visits by 39% (RR 0.61; 95% CI 0.38-0.97). 8

• Reduces need for medical intervention-seeking by 42% (RR 0.58; 95% CI 0.37-0.90) 8
• Consistent efficacy across multiple episodes: conversion in earlier episodes predicts conversion in subsequent episodes 2
• No test dose required before first use in real-world settings (unlike the RAPID trial design) 2, 3

Important Caveat:

Post-hoc analysis suggests etripamil may also reduce ventricular rate in atrial fibrillation (average maximum reduction 27.4 bpm at 22 minutes), though this requires confirmation in dedicated AF trials 7